PDCD1 and non-small cell lung carcinoma: Finally, based on our experimental data combined with previous research results, we established a predictive model for predicting the early efficacy of combined chemotherapy and PD-1 monoclonal antibody therapy in patients with NSCLC based on peripheral blood indicators.